The GLP-1 drama continues at Hims & Hers.Hims & Hers (HIMS 1.85%) fell as much as 12% in trading on Wednesday after pharmaceutical company Novo Nordisk (NVO -0.56%) asked the FDA to not allow companies to compound GLP-1 semaglutide. This could be a direct hit to Hims & Hers business, but the impact may not be what you think, as Travis Hoium covers in this video.*Stock prices used were end-of-day prices of Oct. 23, 2024. The video was published on Oct. 23, 2024. ...